Switzerland: Biosynth expands capabilities with the acquisition of celares

Biosynth, a supplier of raw materials to the life science industry, has acquired Berlin-based  celares, a developer and manufacturer of polymer-based drug delivery excipients and bioconjugate drugs. The acquisition will strengthen and expand Biosynth’s capabilities to offer the bioconjugation of antibodies, antigens, and peptides to its existing pharma and diagnostics customer base. “celares is a…

You must be a HMI Subscriber to view this content.

Subscribe Now »